source
- Cytokinetics reports positive pivotal trial results for aficamten in non-obstructive hypertrophic cardiomyopathyBiotech Cytokinetics disclosed full data from a pivotal study of its drug aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The trial met both primary endpoints, showin…
- FDA approves Roivant's new dermatomyositis therapyThe FDA has granted approval to a therapy developed by Roivant for the treatment of dermatomyositis, a rare autoimmune condition that causes muscle inflammation and skin rash. The decision adds a…